Lidan Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lidan Zhu has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Pei-Yan Kong
Xinqiao Hospital of Army Medical University, Medical Centre of Hematology, Chongqing, China
4 shared publications - Xi Zhang
Medical Center of Hematology, Xinqiao Hospital of Army Medical University, Chongqing, China
4 shared publications Huanfeng Liu
Medical Center of Hematology, State Key Laboratory of Trauma, Burn and Combined Injury, Xinqiao Hospital, Army Medical University, Chongqing, China
3 shared publications- Lei Gao
Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing 400037, China
3 shared publications - Lu Wang
The Fourth Affiliated Hospital of Harbin Medical University Harbin China
3 shared publications Shichun Gao
Medical center of Hematology, Xinqiao Hospital, Army Military Medical University, Chongqing, CHN
3 shared publications
Latest Publications
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 6975
Application Gene Variation Detection before and after Hematopoietic Stem Cell Transplantation to Predict the Relapse of Hematopoietic Neoplasm Patients after Transplantation: Retrospective Data from a Single Center in China
Disclosures. No relevant conflicts of interest to declare.
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 6975
Open AccessApplication Gene Variation Detection before and after Hematopoietic Stem Cell Transplantation to Predict the Relapse of Hematopoietic Neoplasm Patients after Transplantation: Retrospective Data from a Single Center in China
Disclosures. No relevant conflicts of interest to declare.
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e83537cc
P1324: EFFICACY AND SAFETY OF DOSE-ADJUSTED ATG COMBINED WITH CD25 ANTIBODY IN THE PREVENTION OF GVHD AFTER HAPLO-HSCT: CLINICAL STUDY DATA FROM A SINGLE CENTER IN CHINA
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e83537cc
Open AccessP1324: EFFICACY AND SAFETY OF DOSE-ADJUSTED ATG COMBINED WITH CD25 ANTIBODY IN THE PREVENTION OF GVHD AFTER HAPLO-HSCT: CLINICAL STUDY DATA FROM A SINGLE CENTER IN CHINA
- Open Access
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e7027398
PB2433: APPLICATION GENE VARIATION DETECTION BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT THE RELAPSE OF PATIENTS AFTER TRANSPLANTATION: RETROSPECTIVE DATA FROM A SINGLE CENTER IN CHINA
- 8 August 2023
- Published by Wolters Kluwer Health in HemaSphere
- Vol. 7 (S3) , e7027398
Open AccessPB2433: APPLICATION GENE VARIATION DETECTION BEFORE AND AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION TO PREDICT THE RELAPSE OF PATIENTS AFTER TRANSPLANTATION: RETROSPECTIVE DATA FROM A SINGLE CENTER IN CHINA
- Open Access
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Serum Inflammatory Factor Profiles in the Pathogenesis of High‐Altitude Polycythemia and Mechanisms of Acclimation to High Altitudes
High‐altitude polycythemia (HAPC) is a common aspect of chronic mountain sickness (CMS) caused by hypoxia and is the main cause of other symptoms associated with CMS. However, its pathogenesis and the mechanisms of high‐altitude acclimation have not been fully elucidated. Exposure to high altitude is associated with elevated inflammatory mediators. In this study, the subjects were recruited and placed into a plain control (PC) group, plateau control (PUC) group, early HAPC (eHAPC) group, or a confirmed HAPC (cHAPC) group. Serum samples were collected, and inflammatory factors were measured by a novel antibody array methodology. The serum levels of interleukin‐2 (IL‐2), interleukin‐3 (IL‐3), and macrophage chemoattractant protein‐1 (MCP‐1) in the eHAPC group and the levels of interleukin‐1 beta (IL‐1 beta), IL‐2, IL‐3, tumor necrosis factor‐alpha (TNF‐alpha), MCP‐1, and interleukin‐16 (IL‐16) in the cHAPC group were higher than those in the PUC group. More interestingly, the expression of IL‐1 beta, IL‐2, IL‐3, TNF‐alpha, MCP‐1, and IL‐16 in the PUC group showed a remarkable lower value than that in the PC group. These results suggest that these six factors might be involved in the pathogenesis of HAPC as well as acclimation to high altitudes. Altered inflammatory factors might be new biomarkers for HAPC and for high‐altitude acclimation.
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Open AccessSerum Inflammatory Factor Profiles in the Pathogenesis of High‐Altitude Polycythemia and Mechanisms of Acclimation to High Altitudes
High‐altitude polycythemia (HAPC) is a common aspect of chronic mountain sickness (CMS) caused by hypoxia and is the main cause of other symptoms associated with CMS. However, its pathogenesis and the mechanisms of high‐altitude acclimation have not been fully elucidated. Exposure to high altitude is associated with elevated inflammatory mediators. In this study, the subjects were recruited and placed into a plain control (PC) group, plateau control (PUC) group, early HAPC (eHAPC) group, or a confirmed HAPC (cHAPC) group. Serum samples were collected, and inflammatory factors were measured by a novel antibody array methodology. The serum levels of interleukin‐2 (IL‐2), interleukin‐3 (IL‐3), and macrophage chemoattractant protein‐1 (MCP‐1) in the eHAPC group and the levels of interleukin‐1 beta (IL‐1 beta), IL‐2, IL‐3, tumor necrosis factor‐alpha (TNF‐alpha), MCP‐1, and interleukin‐16 (IL‐16) in the cHAPC group were higher than those in the PUC group. More interestingly, the expression of IL‐1 beta, IL‐2, IL‐3, TNF‐alpha, MCP‐1, and IL‐16 in the PUC group showed a remarkable lower value than that in the PC group. These results suggest that these six factors might be involved in the pathogenesis of HAPC as well as acclimation to high altitudes. Altered inflammatory factors might be new biomarkers for HAPC and for high‐altitude acclimation.